Other languages ADMA Biologics, Inc.

Equities

ADMA

US0008991046

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
6.58 ^USD	+0.46%		+0.61%	+45.58%

02/04	ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer	CI
26/03	HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer	03/04
Adma Biologics Insider Sold Shares Worth $2,803,741, According to a Recent SEC Filing	20/03
Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam	11/03
ADMA Biologics Q4 Net Loss Widens, Revenue Rises; Increases 2024, 2025 Revenue Outlook; Seeks Successor for Chief Financial Officer	29/02
ADMA Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025	29/02
ADMA Biologics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
ADMA Biologics Implements ADMAlytics AI Program to Bolster Production	21/02
ADMA Biologics, Inc Successfully Implements Innovative AI Program, Named ADMAlytics	21/02
ADMA Biologics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023, Fiscal Year 2024-2025	08/01
ADMA Biologics Taps $135 Million Credit Facility From Debt Refinancing	19/12
ADMA Biologics, Inc. Announces FDA Approval for BIVIGAM in the Pediatric Patient Setting for Those 2 Years of Age and Older	12/12
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	17/11
ADMA Biologics Obtains US FDA Approval for Plasma Collection Center in Maryland	16/11
ADMA Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
ADMA Biologics, Inc. Updates Financial Guidance for the Years 2023, 2024 and 2025	09/11
ADMA Biologics, Inc. Appoints Alison C. Finger as Class I Director	03/23/03
Insider Buy: Adma Biologics	31/23/31
Insider Sell: Adma Biologics	24/23/24
Insider Sell: Adma Biologics	21/23/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ADMA Biologics, Inc.

Equities

ADMA

US0008991046

Other languages

Filters